Inhaled Treprostinil Successfully Treated Pulmonary Hypertension in Severe Lung Disease
A patient with severe interstitial pneumonia and pulmonary hypertension showed significant improvement with inhaled treprostinil, a prostacyclin analog.
Quick Facts
What This Study Found
Inhaled treprostinil improved BNP levels, tricuspid pressure gradient, and oxygen requirements in a patient with severe interstitial pneumonia and pulmonary hypertension.
Key Numbers
- Patient age: 72 years
- Maximum TRPG before treatment: 64 mmHg
- BNP levels and TRPG improved after inhaled treprostinil
- Oxygen requirement decreased after treatment
How They Did This
Single case report of a 72-year-old male patient.
Why This Research Matters
Demonstrates real-world effectiveness of inhaled treprostinil in a difficult-to-treat patient with combined severe lung disease and pulmonary hypertension.
The Bigger Picture
Inhaled treprostinil is an approved therapy for group 3 pulmonary hypertension, and case reports like this add to the growing evidence of its clinical utility in severe lung disease.
What This Study Doesn't Tell Us
Single case report cannot establish efficacy. Spontaneous improvement or concurrent treatments may have contributed.
Questions This Raises
- ?How durable is the response to inhaled treprostinil in interstitial lung disease?
- ?Should all patients with severe ILD-related PH receive inhaled treprostinil?
Trust & Context
- Key Stat:
- 64 mmHg Initial tricuspid regurgitation pressure gradient before treatment
- Evidence Grade:
- Single case report. Lowest level of clinical evidence but useful for illustrating treatment response.
- Study Age:
- Published in 2025.
- Original Title:
- Pulmonary Hypertension Associated with Severe Interstitial Pneumonia Successfully Treated with Inhaled Treprostinil: A Case Report.
- Published In:
- Internal medicine (Tokyo, Japan) (2025)
- Authors:
- Otsuka, Mitsuki, Sonoda, Shiro, Yamada, Takayuki(2), Aoki, Shotaro, Yasuda, Tomoka, Sawada, Atsushi, Shirai, Tsuyoshi, Tateishi, Tomoya, Furusawa, Haruhiko, Miyazaki, Yasunari
- Database ID:
- RPEP-12894
Evidence Hierarchy
Describes what happened to one person or a small group.
What do these levels mean? →Frequently Asked Questions
What is inhaled treprostinil?
A prostacyclin analog delivered by inhalation that dilates pulmonary blood vessels, reducing pressure in the lungs and improving heart function.
Is this treatment standard for lung disease patients with pulmonary hypertension?
Inhaled treprostinil is the recommended first-choice drug for group 3 pulmonary hypertension (PH associated with chronic lung disease).
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12894APA
Otsuka, Mitsuki; Sonoda, Shiro; Yamada, Takayuki; Aoki, Shotaro; Yasuda, Tomoka; Sawada, Atsushi; Shirai, Tsuyoshi; Tateishi, Tomoya; Furusawa, Haruhiko; Miyazaki, Yasunari. (2025). Pulmonary Hypertension Associated with Severe Interstitial Pneumonia Successfully Treated with Inhaled Treprostinil: A Case Report.. Internal medicine (Tokyo, Japan). https://doi.org/10.2169/internalmedicine.6206-25
MLA
Otsuka, Mitsuki, et al. "Pulmonary Hypertension Associated with Severe Interstitial Pneumonia Successfully Treated with Inhaled Treprostinil: A Case Report.." Internal medicine (Tokyo, 2025. https://doi.org/10.2169/internalmedicine.6206-25
RethinkPeptides
RethinkPeptides Research Database. "Pulmonary Hypertension Associated with Severe Interstitial P..." RPEP-12894. Retrieved from https://rethinkpeptides.com/research/otsuka-2025-pulmonary-hypertension-associated-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.